Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

Background Triple therapy with Pegylated‐Interferon α (PEG‐IFNα)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG‐IFNα/RBV alone (dual therapy). However, less is known...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical investigation 2016-08, Vol.46 (8), p.737-748
Hauptverfasser:	Pecoraro, Valentina, Cariani, Elisabetta, Villa, Erica, Trenti, Tommaso
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - therapeutic use Boceprevir Drug Therapy, Combination Female hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Humans Interferon-alpha - therapeutic use Male meta-analysis Middle Aged Polyethylene Glycols - therapeutic use Proline - analogs & derivatives Proline - therapeutic use Recombinant Proteins - therapeutic use Ribavirin - therapeutic use Telaprevir Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!